[{"source": "PMC", "date": "20230530", "key": "pmc.key", "infons": {}, "documents": [{"id": "2837563", "infons": {"license": "CC BY"}, "passages": [{"offset": 0, "infons": {"alt-title": "Novel K-Ras mutations in human colorectal tumours", "article-id_doi": "10.1038/sj.bjc.6605534", "article-id_pii": "6605534", "article-id_pmc": "2837563", "article-id_pmid": "20147967", "fpage": "693", "issue": "4", "kwd": "K-Ras mutation colorectal tumour gene amplification personalised medicine", "license": "This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.", "lpage": "703", "name_0": "surname:Smith;given-names:G", "name_1": "surname:Bounds;given-names:R", "name_2": "surname:Wolf;given-names:H", "name_3": "surname:Steele;given-names:R J C", "name_4": "surname:Carey;given-names:F A", "name_5": "surname:Wolf;given-names:C R", "section_type": "TITLE", "type": "front", "volume": "102", "year": "2010"}, "text": "Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine", "sentences": [], "annotations": [], "relations": []}, {"offset": 137, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Background:", "sentences": [], "annotations": [], "relations": []}, {"offset": 149, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "Response to EGFR-targeted therapies in colorectal cancer patients has been convincingly associated with Kirsten-Ras (K-Ras) mutation status. Current mandatory mutation testing for patient selection is limited to the K-Ras 'hotspot' codons 12 and 13.", "sentences": [], "annotations": [], "relations": []}, {"offset": 403, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Methods:", "sentences": [], "annotations": [], "relations": []}, {"offset": 412, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "Colorectal tumours (n=106) were screened for additional K-Ras mutations, phenotypes compared in transformation and Ras GTPase activating assays and gene and pathway changes induced by individual K-Ras mutants identified by microarray analysis. Taqman-based gene copy number and FISH analyses were used to investigate K-Ras gene amplification.", "sentences": [], "annotations": [], "relations": []}, {"offset": 755, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Results:", "sentences": [], "annotations": [], "relations": []}, {"offset": 764, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "Four additional K-Ras mutations (Leu19Phe (1 out of 106 tumours), Lys117Asn (1 out of 106), Ala146Thr (7 out of 106) and Arg164Gln (1 out of 106)) were identified. Lys117Asn and Ala146Thr had phenotypes similar to the hotspot mutations, whereas Leu19Phe had an attenuated phenotype and the Arg164Gln mutation was phenotypically equivalent to wt K-Ras. We additionally identified a new K-Ras gene amplification event, present in approximately 2% of tumours.", "sentences": [], "annotations": [], "relations": []}, {"offset": 1221, "infons": {"section_type": "ABSTRACT", "type": "abstract_title_1"}, "text": "Conclusions:", "sentences": [], "annotations": [], "relations": []}, {"offset": 1234, "infons": {"section_type": "ABSTRACT", "type": "abstract"}, "text": "The identification of mutations outwith previously described hotspot codons increases the K-Ras mutation burden in colorectal tumours by one-third. Future mutation screening to facilitate optimal patient selection for treatment with EGFR-targeted therapies should therefore be extended to codon 146, and in addition should consider the unique molecular signatures associated with individual K-Ras mutations.", "sentences": [], "annotations": [], "relations": []}, {"offset": 1642, "infons": {"section_type": "INTRO", "type": "paragraph"}, "text": "Colorectal cancer accounts for approximately 15% of all cancers diagnosed annually in the United Kingdom, and is a major cause of death due to cancer, second only to lung and breast cancer (http://info.cancerresearchuk.org/cancerstats/incidence).